{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T06:31:33Z","timestamp":1794033093337,"version":"4.8.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejca.2021.05.022","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T12:01:08Z","timestamp":1624017668000},"page":"109-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"special_numbering":"C","title":["A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma"],"prefix":"10.1016","volume":"153","author":[{"given":"Anne W.M.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6283-978X","authenticated-orcid":false,"given":"Victor H.F.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6696-3000","authenticated-orcid":false,"given":"Wai-Tong","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primo\u017e","family":"Strojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil F.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7956-6709","authenticated-orcid":false,"given":"Alessandra","family":"Rinaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan P.","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-3682","authenticated-orcid":false,"given":"Arlene A.","family":"Forastiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfio","family":"Ferlito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.05.022_bib1","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1200\/JCO.2015.60.9347","article-title":"Management of nasopharyngeal carcinoma: current practice and future perspective","volume":"33","author":"Lee","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib2","first-page":"879","article-title":"Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas","volume":"140","author":"Niedobitek","year":"1992","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2021.05.022_bib3","first-page":"1461","article-title":"Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin embedded carcinoma specimens","volume":"138","author":"Wu","year":"1991","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ejca.2021.05.022_bib4","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/ijc.2910530507","article-title":"Epstein-Barr virus carriage by nasopharyngeal carcinoma in situ","volume":"53","author":"Yeung","year":"1993","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2013Part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib6","doi-asserted-by":"crossref","first-page":"5222","DOI":"10.1128\/JVI.03614-14","article-title":"Genome diversity of Epstein-Barr virus from multiple tumor types and normal infection","volume":"89","author":"Palser","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.ejca.2021.05.022_bib7","first-page":"1188","article-title":"Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib8","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clon.2010.09.001","article-title":"Different clinical significance of pre- and post-treatment plasma Epstein-Barr virus DNA load in nasopharyngeal carcinoma treated with radiotherapy","volume":"23","author":"Hou","year":"2011","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib10","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1200\/JCO.2006.07.7982","article-title":"Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma","volume":"24","author":"Leung","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/annonc\/mdu117","article-title":"Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma","volume":"25","author":"Leung","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/1471-2407-12-208","article-title":"Role of plasma EBV DNA levels in predicting recurrence of nasopharyngeal carcinoma in a Western population","volume":"12","author":"Ferrari","year":"2012","journal-title":"BMC Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib13","first-page":"2351","article-title":"Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma","volume":"60","author":"Lo","year":"2000","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib14","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma","volume":"94","author":"Chan","year":"2002","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.ejca.2021.05.022_bib15","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/hed.21890","article-title":"Plasma Epstein-Barr virus DNA concentration and clearance rate as novel prognostic factors for metastatic nasopharyngeal carcinoma","volume":"34","author":"Hsu","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2021.05.022_bib16","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/1078-0432.CCR-09-2796","article-title":"Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic\/recurrent nasopharyngeal carcinoma","volume":"16","author":"Wang","year":"2010","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib17","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1002\/cncr.25932","article-title":"Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic\/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy","volume":"117","author":"An","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib18","first-page":"3254","article-title":"Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma","volume":"9","author":"To","year":"2003","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib19","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/hed.20066","article-title":"Quantitative analysis of plasma cell-free Epstein-Barr virus DNA in nasopharyngeal carcinoma after salvage nasopharyngectomy: a prospective study","volume":"26","author":"Wei","year":"2004","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2021.05.022_bib20","doi-asserted-by":"crossref","first-page":"22000","DOI":"10.1038\/srep22000","article-title":"Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy","volume":"6","author":"Peng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejca.2021.05.022_bib21","first-page":"665","article-title":"Epstein-Barr viral DNA in serum of patients with nasopharyngeal carcinoma","volume":"4","author":"Mutirangura","year":"1998","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib22","first-page":"1046","article-title":"Epstein-Barr virus DNA in serum\/plasma as a tumor marker for nasopharyngeal cancer","volume":"6","author":"Shotelersuk","year":"2000","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib23","first-page":"2028","article-title":"Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients","volume":"63","author":"Chan","year":"2003","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib24","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/cncr.20099","article-title":"Comparison of plasma Epstein\u2013Barr virus (EBV) DNA levels and serum EBV immunoglobulin A\/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma","volume":"100","author":"Shao","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1373\/clinchem.2003.022426","article-title":"Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody","volume":"50","author":"Leung","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.ejca.2021.05.022_bib26","first-page":"4059","article-title":"Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma","volume":"24","author":"Shao","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ijrobp.2006.07.012","article-title":"Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma","volume":"67","author":"Twu","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.022_bib28","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.otohns.2006.11.053","article-title":"Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States","volume":"136","author":"Tm","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2021.05.022_bib29","first-page":"76","article-title":"Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma","volume":"28","author":"Luo","year":"2009","journal-title":"Ai Zheng"},{"key":"10.1016\/j.ejca.2021.05.022_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jcv.2012.05.017","article-title":"Clinical significance of plasma Epstein-Barr virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma","volume":"55","author":"Chai","year":"2012","journal-title":"J Clin Virol"},{"key":"10.1016\/j.ejca.2021.05.022_bib31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/cncr.10251","article-title":"Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma","volume":"94","author":"Hsiao","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib32","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ijc.11130","article-title":"EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma","volume":"105","author":"Chan","year":"2003","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib33","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1349-7006.2004.tb03241.x","article-title":"Diagnostic value of serum EBV-DNA quantification and antibody to viral capsid antigen in nasopharyngeal carcinoma patients","volume":"95","author":"Kondo","year":"2004","journal-title":"Canc Sci"},{"key":"10.1016\/j.ejca.2021.05.022_bib34","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ijc.20520","article-title":"Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus","volume":"112","author":"Fan","year":"2004","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib35","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/jjco\/hyh055","article-title":"Serum EBV DNA as a biomarker in primary nasopharyngeal carcinoma of Indian origin","volume":"34","author":"Krishna","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ijc.21396","article-title":"Distribution of Epstein-Barr viral load in serum of individuals from nasopharyngeal carcinoma high-risk families in Taiwan","volume":"118","author":"Yang","year":"2006","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib37","first-page":"1173","article-title":"Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen","volume":"122","author":"Mo","year":"2009","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ejca.2021.05.022_bib38","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00405-011-1717-5","article-title":"Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia","volume":"269","author":"Baizig","year":"2012","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.ejca.2021.05.022_bib39","first-page":"5452","article-title":"Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib40","doi-asserted-by":"crossref","first-page":"105128","DOI":"10.1016\/j.oraloncology.2020.105128","article-title":"The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: comprehensive clinical practice guidelines evaluation","volume":"114","author":"Trevisiol","year":"2021","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib41","series-title":"Head and Neck cancers version 1.2021 \u2013 November 9, 2020","year":"2020"},{"issue":"20","key":"10.1016\/j.ejca.2021.05.022_bib42","first-page":"43210","article-title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"S0923\u20137534","author":"Bossi","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib43","first-page":"6878","article-title":"Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA","volume":"60","author":"Lo","year":"2000","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/cncr.11496","article-title":"Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type","volume":"98","author":"Leung","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib45","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ijrobp.2007.02.012","article-title":"Long-term prognostic effects of plasma Epstein-Barr Virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy","volume":"68","author":"Lin","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.022_bib46","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1002\/cncr.26069","article-title":"Plasma Epstein-Barr virus DNA screening followed by 18F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma","volume":"117","author":"Wang","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2967\/jnumed.111.090696","article-title":"Prognostic significance of 18F-FDG PET parameters and plasma Epstein-Barr virus DNA load in patients with nasopharyngeal carcinoma","volume":"53","author":"Chang","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib48","first-page":"976","article-title":"Is pre-treatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma?","volume":"8","author":"Jin","year":"2017","journal-title":"J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib49","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/cncr.28001","article-title":"Early detection of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA analysis in a surveillance program","volume":"119","author":"Chan","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib50","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/cncr.27853","article-title":"Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib51","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijrobp.2014.01.052","article-title":"Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid","volume":"89","author":"Twu","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.022_bib52","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/cncr.28564","article-title":"Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China","volume":"120","author":"Ji","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib53","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000360178","article-title":"Pre-treatment Epstein-Barr virus DNA load and cumulative cisplatin dose intensity affect long-term outcome of nasopharyngeal carcinoma treated with concurrent chemotherapy: experience of an institute in an endemic area","volume":"37","author":"Wei","year":"2014","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ejca.2021.05.022_bib54","doi-asserted-by":"crossref","first-page":"e845","DOI":"10.1097\/MD.0000000000000845","article-title":"The clinical utility of plasma Epstein-Barr virus DNA assays in nasopharyngeal carcinoma: the dawn of a new era? A systematic review and meta-analysis of 7836 cases","volume":"94","author":"Zhang","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejca.2021.05.022_bib55","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ijrobp.2015.08.003","article-title":"The prognostic value of plasma Epstein-Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma","volume":"93","author":"Liu","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.022_bib56","article-title":"Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET\/CT for nasopharyngeal carcinoma patients with recurrence","volume":"10","author":"Shen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2021.05.022_bib57","first-page":"617949","article-title":"Impact of plasma Epstein-Barr virus-DNA and tumor volume on prognosis of locally advanced nasopharyngeal carcinoma","volume":"2015","author":"Chen","year":"2015","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ejca.2021.05.022_bib58","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001945","article-title":"Plasma Epstein-Barr viral deoxyribonucleic acid predicts worse outcomes in pediatric nonmetastatic nasopharyngeal carcinoma patients: an observational study of 89 cases in an endemic area","volume":"94","author":"Shen","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejca.2021.05.022_bib59","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.clon.2015.09.009","article-title":"Post-radiation plasma Epstein-Barr virus DNA and local clinical remission after radical intensity-modulated radiation therapy for nasopharyngeal carcinoma","volume":"28","author":"Lee","year":"2016","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib60","article-title":"Epstein-Barr virus DNA level a novel prognostic factor in nasopharyngeal carcinoma: a meta-analysis","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejca.2021.05.022_bib61","doi-asserted-by":"crossref","first-page":"djv291","DOI":"10.1093\/jnci\/djv291","article-title":"Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma","volume":"108","author":"Tang","year":"2015","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.ejca.2021.05.022_bib62","article-title":"Prognostic value of plasma Epstein-Barr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era","volume":"95","author":"Chen","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.ejca.2021.05.022_bib63","first-page":"664","article-title":"Circulating EBV DNA, globulin and nodal size predict distant metastasis after intensity-modulated radiotherapy in stage II nasopharyngeal carcinoma","volume":"7","author":"Du","year":"2016","journal-title":"J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib64","doi-asserted-by":"crossref","first-page":"42608","DOI":"10.18632\/oncotarget.9323","article-title":"Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2021.05.022_bib65","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.18632\/oncotarget.6754","article-title":"Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2021.05.022_bib66","doi-asserted-by":"crossref","first-page":"9576","DOI":"10.18632\/oncotarget.7083","article-title":"Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2021.05.022_bib67","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3892\/ol.2015.3628","article-title":"Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma","volume":"10","author":"Zhao","year":"2015","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejca.2021.05.022_bib68","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa1701717","article-title":"Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer","volume":"377","author":"Chan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib69","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.18632\/oncotarget.14137","article-title":"Prognostication of serial post-intensity-modulated radiation therapy undetectable plasma EBV DNA for nasopharyngeal carcinoma","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2021.05.022_bib70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.oraloncology.2017.04.015","article-title":"Establishing and applying nomograms based on the 8th edition of the UICC\/AJCC staging system to select patients with nasopharyngeal carcinoma who benefit from induction chemotherapy plus concurrent chemoradiotherapy","volume":"69","author":"Xu","year":"2017","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib71","first-page":"87","article-title":"Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy","volume":"36","author":"Li","year":"2017","journal-title":"Chin J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib72","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.25011\/cim.v40i1.28049","article-title":"Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis","volume":"40","author":"Liu","year":"2017","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib73","doi-asserted-by":"crossref","first-page":"861","DOI":"10.4143\/crt.2017.237","article-title":"Combination of tumor volume and Epstein-Barr virus DNA improved prognostic stratification of stage II nasopharyngeal carcinoma in the intensity modulated radiotherapy era: a large-scale cohort study","volume":"50","author":"Chen","year":"2018","journal-title":"Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.05.022_bib74","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/jrr\/rrw128","article-title":"Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma","volume":"58","author":"Prayongrat","year":"2017","journal-title":"J Radiat Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib75","article-title":"Analysis of plasma Epstein-Barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: a randomized controlled trial","author":"Chan","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2478\/raon-2018-0016","article-title":"Prognostic value of plasma EBV DNA for nasopharyngeal cancer patients during treatment with intensity-modulated radiation therapy and concurrent chemotherapy","volume":"52","author":"Lertbutsayanukul","year":"2018","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib77","first-page":"3352","volume":"9","author":"Zhou","year":"2018","journal-title":"J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib78","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7150\/ijbs.24374","article-title":"Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics","volume":"14","author":"Li","year":"2018","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.ejca.2021.05.022_bib79","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4143\/crt.2017.180","article-title":"Pre-treatment serum amyloid A and C-reactive protein comparing with Epstein-Barr virus DNA as prognostic indicators in patients with nasopharyngeal carcinoma: a prospective study","volume":"50","author":"Chen","year":"2018","journal-title":"Canc Res Treat"},{"key":"10.1016\/j.ejca.2021.05.022_bib80","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/cam4.1381","article-title":"Dynamic changes in plasma Epstein-Barr virus DNA load during treatment have prognostic value in nasopharyngeal carcinoma: a retrospective study","volume":"7","author":"He","year":"2018","journal-title":"Canc Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib81","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918782331","article-title":"The plasma Epstein-Barr virus DNA level guides precision treatment for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a large population-based cohort study from an endemic area","volume":"10","author":"Liang","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib82","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1089\/gtmb.2018.0304","article-title":"Molecular prognostic value of circulating Epstein-Barr viral DNA in nasopharyngeal carcinoma: a meta-analysis of 27,235 cases in the endemic area of Southeast Asia","volume":"23","author":"Xie","year":"2019","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.ejca.2021.05.022_bib83","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1002\/ijc.31856","article-title":"The addition of pre-treatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification","volume":"144","author":"Lee","year":"2019","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib84","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/cncr.31741","article-title":"Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma","volume":"125","author":"Guo","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib85","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1038\/s41467-019-11853-y","article-title":"Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma","volume":"10","author":"Lv","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2021.05.022_bib86","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2018.10.010","article-title":"Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma","volume":"132","author":"Liang","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib87","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41416-019-0575-6","article-title":"Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes","volume":"121","author":"Nicholls","year":"2019","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib88","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12885-019-5281-5","article-title":"Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib89","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1002\/cam4.2481","article-title":"Combining pre-treatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: a cohort study","volume":"8","author":"Du","year":"2019","journal-title":"Canc Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib90","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/jjco\/hyz109","volume":"49","author":"Kitpanit","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib91","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1002\/cam4.2339","article-title":"Clinical characteristics and prognostic value of pre-retreatment plasma Epstein-Barr virus DNA in locoregional recurrent nasopharyngeal carcinoma","volume":"8","author":"Liu","year":"2019","journal-title":"Canc Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib92","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2019.01.007","article-title":"Plasma epstein-barr virus DNA load after induction chemotherapy predicts outcome in locoregionally advanced nasopharyngeal carcinoma","volume":"104","author":"Huang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.022_bib93","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s00259-018-4172-3","article-title":"Value of early evaluation of treatment response using 18F-FDG PET\/CT parameters and the Epstein-Barr virus DNA load for prediction of outcome in patients with primary nasopharyngeal carcinoma","volume":"46","author":"Chen","year":"2019","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.ejca.2021.05.022_bib94","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/ijc.32380","article-title":"Relationship of circulating tumor cells and Epstein\u2013Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients","volume":"145","author":"You","year":"2019","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib95","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3389\/fonc.2020.01417","article-title":"Prognostication of half-life clearance of plasma EBV DNA in previously untreated non-metastatic nasopharyngeal carcinoma treated with radical intensity-modulated radiation therapy","volume":"10","author":"Chan","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib96","doi-asserted-by":"crossref","first-page":"703","DOI":"10.6004\/jnccn.2018.7270","article-title":"Neoadjuvant or adjuvant chemotherapy plus concurrent CRT versus concurrent CRT alone in the treatment of nasopharyngeal carcinoma: a study based on EBV DNA","volume":"17","author":"Liu","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2021.05.022_bib97","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.3389\/fonc.2020.01469","article-title":"Clinical characteristics and prognostic factors of early and late recurrence after definitive radiotherapy for nasopharyngeal carcinoma","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920932052","article-title":"Risk stratification for nasopharyngeal carcinoma: a real-world study based on locoregional extension patterns and Epstein-Barr virus DNA load","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib99","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3389\/fonc.2020.00618","article-title":"Predicting progression-free survival using MRI-based radiomics for patients with nonmetastatic nasopharyngeal carcinoma","volume":"10","author":"Shen","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib100","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fonc.2020.00356","article-title":"Clinical implications of plasma Epstein-Barr virus DNA in children and adolescent nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy","volume":"10","author":"Qiu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib101","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.annonc.2020.03.289","article-title":"Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy","volume":"31","author":"Hui","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib102","doi-asserted-by":"crossref","first-page":"83","DOI":"10.21037\/atm.2020.01.13","article-title":"Establishing M1 stage subdivisions by incorporating radiological features and Epstein-Barr virus DNA for metastatic nasopharyngeal carcinoma","volume":"8","author":"Zheng","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib103","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/cncr.32770","article-title":"Prognostic potential of liquid biopsy tracking in the posttreatment surveillance of patients with nonmetastatic nasopharyngeal carcinoma","volume":"126","author":"Chen","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2021.05.022_bib104","doi-asserted-by":"crossref","first-page":"104628","DOI":"10.1016\/j.oraloncology.2020.104628","article-title":"Pretreatment 18F-FDG-PET\/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma","volume":"104","author":"Lin","year":"2020","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib105","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1002\/cam4.2926","article-title":"Effects of oral maintenance chemotherapy and predictive value of circulating EBV DNA in metastatic nasopharyngeal carcinoma","volume":"9","author":"Zhou","year":"2020","journal-title":"Canc Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib106","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ejca.2021.05.022_bib107","first-page":"djaa198","article-title":"Cost-effectiveness of nasopharyngeal carcinoma screening with Epstein-Barr virus polymerase chain reaction or serology in high-incidence populations worldwide","author":"Miller","year":"2020","journal-title":"J Natl Canc Inst"},{"key":"10.1016\/j.ejca.2021.05.022_bib108","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1158\/1078-0432.CCR-08-1112","article-title":"Quantitative analysis of the transrenal excretion of circulating EBV DNA in nasopharyngeal carcinoma patients","volume":"14","author":"Chan","year":"2008","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib109","series-title":"NRG-HN001 protocol information randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr Virus (EBV) deoxyribonucleic acid (DNA)","year":"2020"},{"key":"10.1016\/j.ejca.2021.05.022_bib110","first-page":"302","article-title":"Significance of cell-free Epstein\u2013Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma","volume":"22","author":"Cao","year":"2003","journal-title":"Ai Zheng"},{"key":"10.1016\/j.ejca.2021.05.022_bib111","first-page":"3431","article-title":"Disparity of sensitivities in detection of radiation-naive and postirradiation recurrent nasopharyngeal carcinoma of the undifferentiated type by quantitative analysis of circulating Epstein\u2013Barr virus DNA","volume":"9","author":"Leung","year":"2003","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib112","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.oraloncology.2013.02.006","article-title":"Clinical scenario of EBV DNA follow-up in patients of treated localized nasopharyngeal carcinoma","volume":"49","author":"Hsu","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2021.05.022_bib113","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1158\/1078-0432.CCR-12-3702","article-title":"An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma","volume":"19","author":"Le","year":"2013","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.05.022_bib114","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ijrobp.2017.03.018","article-title":"Clinical utility of Epstein-Barr virus DNA testing in the treatment of nasopharyngeal carcinoma patients","volume":"98","author":"Kim","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.022_bib115","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1056\/NEJMc1800433","article-title":"Ambient temperature and screening for nasopharyngeal cancer","volume":"378","author":"Chan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib116","first-page":"475","article-title":"The biology and clinical utility of EBV monitoring in blood","volume":"391","author":"Kanakry","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.ejca.2021.05.022_bib117","doi-asserted-by":"crossref","first-page":"E5115","DOI":"10.1073\/pnas.1804184115","article-title":"Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma","volume":"115","author":"Lam","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2021.05.022_bib118","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12916-017-0921-6","article-title":"Circulating tumor DNA for personalized lung cancer monitoring","volume":"15","author":"Fiala","year":"2017","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib119","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijrobp.2017.08.034","article-title":"In regard to Kim et\u00a0al","volume":"99","author":"Zoto Mustafayev","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2021.05.022_bib120","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1002\/ijc.31642","article-title":"Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma","volume":"143","author":"Jiang","year":"2018","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib121","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s10020-019-0112-3","article-title":"Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma","volume":"25","author":"Qu","year":"2019","journal-title":"Mol Med"},{"key":"10.1016\/j.ejca.2021.05.022_bib122","first-page":"2537","article-title":"Detection and clinical significance of circulating tumor cells in patients with nasopharyngeal carcinoma","volume":"18","author":"Wen","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejca.2021.05.022_bib123","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/s41416-020-0871-1","article-title":"Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma","volume":"123","author":"Ko","year":"2020","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2021.05.022_bib124","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jjco\/hyw046","article-title":"Distribution and clinical significance of circulating tumor cells in nasopharyngeal carcinoma","volume":"46","author":"Si","year":"2016","journal-title":"Jpn J Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921003312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:32:56Z","timestamp":1760733176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921003312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":124,"alternative-id":["S0959804921003312"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.022","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}